Ask AI
ProCE Banner Activity

Roadmap to Maximizing Efficacy and Enhancing Tolerability With Antibody–Drug Conjugates in HER2-Negative Advanced Breast Cancer: An Oncology Nursing Pocket Guide for Sacituzumab Govitecan and Datopotamab Deruxtecan

PDF

Downloadable pocket guide to assist oncology nurses in quickly identifying and assessing the severity of ADC-related adverse events associated with sacituzumab govitecan and datopotamab deruxtecan in the management of patients with HR-positive, HER2-negative metastatic breast cancer, including the evolving nursing role, factors that nurses should consider to deliver safe and high-quality care, measures to use to optimize the early recognition of adverse events, and institute early intervention to improve adherence while utilizing shared treatment decision-making approaches to optimize treatment outcomes.

Released: September 22, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity is intended for oncology nurses and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss how structural, mechanistic, and unique characteristics, including the “bystander effect,” of antibody–drug conjugates contribute to differing toxicities and adverse event profiles

  • Identify and manage toxicities associated with TROP2-directed ADCs in breast cancer, applying strategies to mitigate these adverse events effectively

  • Integrate patients’ treatment goals, preferences, and quality of life considerations into decisions related to ADC therapy selection and supportive care

Financial Disclosures

Primary Author

Ashley Martinez, PhD, DNP, APRN, FNP-BC, AOCNP, CPHQ, NEA-BC, NPD-BC: consultant/advisor/speaker: Curio.